The acute effect of a single application of cabergoline on endogenous GH levels in patients with acromegaly on pegvisomant treatment

Growth Hormone and IGF Research

Volumn 20, Issue 5, 2010, Pages 338-344

  Roemmler, J ^a   Steffin, B ^a   Gutt, B ^b   Schneider, H J ^a   Sievers, C ^c   Bidlingmaier, M ^a   Schopohl, J ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Acromegaly; Acute effect; Combined medical treatment; Dopamine agonist; Endogenous GH; Growth hormone receptor antagonist

Indexed keywords

CABERGOLINE; GROWTH HORMONE; INSULIN; METFORMIN; PEGVISOMANT;

ACROMEGALY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; FOOD INTAKE; GROWTH HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REFERENCE VALUE; SINGLE DRUG DOSE;

ACROMEGALY; ADULT; AGED; BLOOD GLUCOSE; CROSS-SECTIONAL STUDIES; ERGOLINES; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; RECEPTORS, SOMATOTROPIN;

EID: 77957119638     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2010.05.004     Document Type: Article

References (39)

1. Paisley A.N., Hayden K., Ellis A., Anderson J., Wieringa G., Trainer P.J. Pegvisomant interference in GH assays results in underestimation of GH levels. Eur. J. Endocrinol. 2007, 156:315-319.
2. Thorner M.O., Strasburger C.J., Wu Z., et al. Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH. J. Clin. Endocrinol. Metab. 1999, 84:2098-2103.
3. Kopchick J.J., Parkinson C., Stevens E.C., Trainer P.J. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr. Rev. 2002, 23:623-646.
4. van der Lely A.J., Hutson R.K., Trainer P.J., et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001, 358:1754-1759.
5. Schreiber I., Buchfelder M., Droste M., et al. Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur. J. Endocrinol. 2007, 156:75-82.
6. Trainer P.J., Drake W.M., Katznelson L., et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N. Engl. J. Med. 2000, 342:1171-1177.
7. Veldhuis J.D., Bidlingmaier M., Anderson S.M., Wu Z., Strasburger C.J. Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men. J. Clin. Endocrinol. Metab. 2001, 86:3304-3310.
8. Roemmler J., Steffin B., Gutt B., Sievers C., Bidlingmaier M., Schopohl J. The effect of acute application of pegvisomant alone and in combination with octreotide on endogenous GH levels during a 6-h test in patients with acromegaly on constant pegvisomant treatment. Growth Horm. IGF Res. 2009, 19:245-251.
9. Jorgensen J.O., Feldt-Rasmussen U., Frystyk J., et al. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J. Clin. Endocrinol. Metab. 2005, 90:5627-5631.
10. Veldhuis J.D., Bidlingmaier M., Anderson S.M., Evans W.S., Wu Z., Strasburger C.J. Impact of experimental blockade of peripheral growth hormone (GH) receptors on the kinetics of endogenous and exogenous GH removal in healthy women and men. J. Clin. Endocrinol. Metab. 2002, 87:5737-5745.
11. Feenstra J., de Herder W.W., ten Have S.M., et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 2005, 365:1644-1646.
12. Neggers S.J., van Aken M.O., Janssen J.A., Feelders R.A., de Herder W.W., van der Lely A.J. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J. Clin. Endocrinol. Metab. 2007, 92:4598-4601.
13. Melmed S., Casanueva F., Cavagnini F., et al. Consensus statement: medical management of acromegaly. Eur. J. Endocrinol. 2005, 153:737-740.
14. Colao A., Lombardi G., Annunziato L. Cabergoline. Expert Opin. Pharmacother. 2000, 1:555-574.
15. Abs R., Verhelst J., Maiter D., et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J. Clin. Endocrinol. Metab. 1998, 83:374-378.
16. Freda P.U., Reyes C.M., Nuruzzaman A.T., Sundeen R.E., Khandji A.G., Post K.D. Cabergoline therapy of growth hormone & growth hormone/prolactin secreting pituitary tumors. Pituitary 2004, 7:21-30.
17. Cozzi R., Attanasio R., Barausse M., et al. Cabergoline in acromegaly: a renewed role for dopamine agonist treatment?. Eur. J. Endocrinol. 1998, 139:516-521.
18. Jackson S.N., Fowler J., Howlett T.A. Cabergoline treatment of acromegaly: a preliminary dose finding study. Clin. Endocrinol. (Oxf.) 1997, 46:745-749.
19. Cozzi R., Attanasio R., Lodrini S., Lasio G. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin. Endocrinol. (Oxf.) 2004, 61:209-215.
20. Selvarajah D., Webster J., Ross R., Newell-Price J. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. Eur. J. Endocrinol. 2005, 152:569-574.
21. Minniti G., Jaffrain-Rea M.L., Baldelli R., et al. Acute effects of octreotide, cabergoline and a combination of both drugs on GH secretion in acromegalic patients. Clin. Ter. 1997, 148:601-607.
22. Marzullo P., Ferone D., Di Somma C., et al. Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. Pituitary 1999, 1:115-120.
23. Higham C.E., Atkinson A.B., Alywin S., Martin N.M., Moyes V., Newell-Price J., Trainer P.J. A Prospective Clinical Trial of Combined Cabergoline (C) and Pegvisomant (pegV) Treatment in Patients with Active Acromegaly, Meeting of the Endocrine Society (Abstract) 2009.
24. Higham C.E., Chung T.T., Lawrance J., Drake W.M., Trainer P.J. Long-term experience of pegvisomant therapy as a treatment for acromegaly. Clin. Endocrinol. (Oxf.) 2009, 71:86-91.
25. Elmlinger M.W., Kuhnel W., Weber M.M., Ranke M.B. Reference ranges for two automated chemiluminescent assays for serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3). Clin. Chem. Lab. Med. 2004, 42:654-664.
26. Del Dotto P., Bonuccelli U. Clinical pharmacokinetics of cabergoline. Clin. Pharmacokinet. 2003, 42:633-645.
27. Bristow A.F., Gooding R.P., Das R.E. The international reference reagent for insulin-like growth factor-I. J. Endocrinol. 1990, 125:191-197.
28. Muller A.F., Janssen J.A., Hofland L.J., et al. Blockade of the growth hormone (GH) receptor unmasks rapid GH-releasing peptide-6-mediated tissue-specific insulin resistance. J. Clin. Endocrinol. Metab. 2001, 86:590-593.
29. Ferrari C., Paracchi A., Romano C., et al. Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients. Clin. Endocrinol. (Oxf.) 1988, 29:467-476.
30. Herlihy O.M., Perros P. Elevated serum growth hormone in a patient with Type 1 diabetes: a diagnostic dilemma. Diabetes Metab. Res. Rev. 2000, 16:211-216.
31. Kayath M.J., Russo E.M., Dib S.A., Vieira J.G. Do impaired glucose tolerance and diabetes mellitus interfere with the interpretation of the growth hormone response to the oral glucose tolerance test?. Braz. J. Med. Biol. Res. 1992, 25:449-455.
32. Barkan A.L., Halasz I., Dornfeld K.J., et al. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J. Clin. Endocrinol. Metab. 1997, 82:3187-3191.
33. Jenkins P.J., Bates P., Carson M.N., Stewart P.M., Wass J.A. Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly. J. Clin. Endocrinol. Metab. 2006, 91:1239-1245.
34. Schusdziarra V., Schmid R. Physiological and pathophysiological aspects of somatostatin. Scand. J. Gastroenterol. Suppl. 1986, 119:29-41.
35. Pijl H., Ohashi S., Matsuda M., et al. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diab. Care 2000, 23:1154-1161.
36. Aminorroaya A., Janghorbani M., Ramezani M., Haghighi S., Amini M. Does bromocriptine improve glycemic control of obese type-2 diabetics?. Horm. Res. 2004, 62:55-59.
37. Cincotta A.H., Meier A.H. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diab. Care 1996, 19:667-670.
38. Landgraf R., Landraf-Leurs M.M., Weissmann A., Horl R., von Werder K., Scriba P.C. Prolactin: a diabetogenic hormone. Diabetologia 1977, 13:99-104.
39. Kamath V., Jones C.N., Yip J.C., et al. Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women. Diab. Care 1997, 20:1697-1701.